Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
News
Biotech
23/11/2021
Biotech Show Case: looking for partners to pursue the development of our Nanocyclix® technology products together!
Meet Dr. Jan Hoflack during Biotech ShowCase to explore our products pipeline using our technological module Nanocyclix®.
Biotech
04/11/2021
ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
Corporate
A.I
28/10/2021
Oncodesign: EHDEN Certified SME
EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.
Corporate
Financial
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Biotech
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
20/10/2021
[WEBINARS] Pharmaco-imaging, COVID-19, Microbiome…
[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar
Service
19/10/2021
[CONGRESS] Discovery UK: 26 – 27 October 2021
Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.
Financial
16/09/2021
Oncodesign announces its results for the first half of 2021
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Corporate
Financial
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Corporate
02/07/2021
Find out how we built our logo!
Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!
Corporate
01/07/2021
Brand new logo for Oncodesign
Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.
Biotech
Financial
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.